TY - JOUR
T1 - Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY)
T2 - a randomised controlled, open-label, platform trial
AU - RECOVERY Collaborative Group
AU - Abani, Obbina
AU - Abbas, Ali
AU - Abbas, Fatima
AU - Abbas, Mustafa
AU - Abbasi, Sadia
AU - Abbass, Hakam
AU - Abbott, Alfie
AU - Abdallah, Nabeel
AU - Abdelaziz, Ashraf
AU - Abdelfattah, Mohamed
AU - Abdelqader, Bushra
AU - Abdo, David
AU - Abdul, Basir
AU - Abdul Rasheed, Althaf
AU - Abdulakeem, Ajibode
AU - Abdul-Kadir, Rezan
AU - Abdulle, Amina
AU - Abdulmumeen, Abdulfatahi
AU - Abdul-Raheem, Rasheed
AU - Abdulshukkoor, Niyaz
AU - Abdusamad, Kula
AU - Abed El Khaleq, Yazeed
AU - Abedalla, Mai
AU - Abeer Ul Amna, Abeer Ul Amna
AU - Abernethy, Katrina
AU - Aboaba, Adebanke
AU - Abo-Leyah, Hani
AU - Abou-Haggar, Ahmed
AU - Abouibrahim, Mahmoud
AU - Abraham, Miriam
AU - Abraham, Tizzy
AU - Abraheem, Abraheem
AU - Abrams, Judith
AU - Abu, Hyacinth John
AU - Abu-Arafeh, Ahmed
AU - Abubacker, Syed M.
AU - Abung, Akata
AU - Aceampong, Yaa
AU - Achara, Amaka
AU - Acharya, Devikumar
AU - Acheampong, Sarah
AU - Acheson, Janet
AU - Acosta, Andres
AU - Acton, Catherine
AU - Adabie-Ankrah, Jacqueline
AU - Adair, Sara
AU - Adam, Fiona
AU - Adam, Matthew
AU - Adamali, Huzaifa
AU - Adams, Carol
AU - Adams, Charlotte
AU - Adams, Kate
AU - Adams, Lisa
AU - Adams, Richard
AU - Adams, Tim
AU - Adcock, Kirsty
AU - Addai, Jemaimah
AU - Adebiyi, Ade
AU - Adegoke, Ken
AU - Adell, Vicki
AU - Ademokun, Debo
AU - Adenwalla, Sherna
AU - Adesemoye, Oluwasegun A.
AU - Adewunmi, Emmanuel O.
AU - Adeyemi, Joyce
AU - Adhikary, Rina
AU - Adkins, Gabrielle
AU - Adnan, Adnan
AU - Aeron-Thomas, John
AU - Affleck, Debbie
AU - Affron, Dominic
AU - Afnan, Carmel
AU - Afridi, Muhammad
AU - Aftab, Zainab A.
AU - Agarwal, Meenakshi
AU - Agbeko, Rachel
AU - Agbo, Chris
AU - Agent, Penny
AU - Aggarwal, Sunil
AU - Aghababaie, Arameh
AU - Ahamed Sadiq, Shafana
AU - Ahammed Nazeer, Mohamed H.
AU - Ahmad, Humayun
AU - Ahmad, Mohammad
AU - Ahmad, Syed
AU - Ahmed, Asim
AU - Ahmed, Bilal
AU - Ahmed, Forizuddin
AU - Ahmed, Hamze
AU - Ahmed, Iram
AU - Ahmed, Irshad
AU - Ahmed, Khaled
AU - Ahmed, Liban
AU - Ahmed, Mahin
AU - Ahmed, Maria C.
AU - Ahmed, Muhammad S.
AU - Ahmed, Naseer
AU - Ahmed, Nausheen
AU - Ahmed, Osama
AU - Ahmed, Rajia A.
AU - Ahmed, Rizwan
AU - Ahmed, Saif
AU - Ahmed, Sammiya
AU - Ahmed, Sara
AU - Ahmed, Sophia
AU - Ahmed, Syed
AU - Ahmed, Syed Haris
AU - Ahmed Ali, Roa
AU - Ahmed, Sana
AU - Ahmer, Sana
AU - Ail, Dhiraj
AU - Ainsworth, Mark
AU - Airoldi, Giulia
AU - Aissa, Myriam
AU - Aitken, Lindianne
AU - Ajay, Bini
AU - Ajeneye, Francis
AU - Ajibode, Abdulakeem
AU - Ajmi, Ayesha
AU - Akbar, Tahir
AU - Akhtar, Naim
AU - Akhtar, Nasim
AU - Akhtar, Nauman
AU - Akili, Suha
AU - Akindolie, Oludoyinsola
AU - Akinfenwa, Yinka
AU - Akinkugbe, Olugbenga
AU - Akinpelu, Ibrahim
AU - Akinwumiju, Olajide
AU - Aktinade, Olugbenro
AU - Al Aaraj, Ahmad
AU - Al Balushi, Asma
AU - Al Dakhola, Majd
AU - Al Swaifi, Aladdin
AU - Al-Abadi, Eslam
AU - Aladangady, Narendra
AU - Alam, Ayaz
AU - Alam, Sajid
AU - Al-Asadi, Abbas
AU - Al-Asadi, Karina
AU - Alatzoglou, Kyriaki
AU - Al-Bayati, Manaf
AU - Albert, Paul
AU - Albon, Lorraine
AU - Alcorn, Gemma
AU - Alcorn, Stephen
AU - Aldana, Aggie
AU - Alderdice, David
AU - Aldouri, Rayan
AU - Aldridge, Jonathan
AU - Aldridge, Nicolas
AU - Alegria, Ana
AU - Alexander, Alison
AU - Alexander, John
AU - Alexander, Peter D.G.
AU - Alford, Charlotte
AU - Al-Fori, Julyan
AU - Alghazawi, Laith
AU - Al-Hakim, Bahij
AU - Al-Hity, Shams
AU - Ali, Ali
AU - Ali, Asad
AU - Ali, Fawzia R.
AU - Ali, Hoodo
AU - Ali, Jawad
AU - Ali, Mariam
AU - Ali, Mohammad
AU - Ali, Nayab
AU - Ali, Oudai
AU - Ali, Sabira
AU - Ali, Sakina
AU - Ali, Syed
AU - Alina, Abid
AU - Aliyuda, Fine
AU - Alizadeh, Katrin
AU - Al-Jibury, Maithem
AU - Al-Juboori, Saba
AU - Al-Khalil, Majid
AU - Alkhusheh, Moutaz
AU - Allameddine, Allameddine
AU - Allan, Fiona
AU - Allan, Rachel
AU - Allanson, Alison
AU - Allcock, Robert
AU - Allen, Beverley
AU - Allen, Eireann
AU - Allen, Jess
AU - Allen, Kerry
AU - Allen, Laura
AU - Allen, Louise
AU - Allen, Poppy
AU - Allen, Rebecca
AU - Allen, Sam
AU - Allen, Sharon
AU - Allen, Simon
AU - Allison, Kathryn
AU - Allman, Bethan
AU - Allsop, Lynne
AU - Al-Moasseb, Hassan
AU - Johnson, Emma
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2021/5/29
Y1 - 2021/5/29
N2 - Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
AB - Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
UR - http://www.scopus.com/inward/record.url?scp=85106644551&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(21)00897-7
DO - 10.1016/S0140-6736(21)00897-7
M3 - Article
C2 - 34000257
AN - SCOPUS:85106644551
SN - 0140-6736
VL - 397
SP - 2049
EP - 2059
JO - The Lancet
JF - The Lancet
IS - 10289
ER -